Correction Notice: Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial

Since the publication of the article entitled “Immunochemotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial” (HemaSphere. 2022;6(3):e699), the authors have indicated an updated author contributions section. This has now been adjusted.

The changes have been made online: https://journals.lww.com/hemasphere/Fulltext/2022/03000/Immunochemotherapy_and_Maintenance_With.9.aspx